HOOK OTC
HOOKIPA Pharma Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +28.5%
1Y: +0.9%
3Y: -86.8%
5Y: -98.7%
$1.15
Last traded 2026-07-17 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-02-15
Earliest Filing
2025-05-22
Latest Filing
partner: 4
acquirer: 1
investor: 1
Counterparties (Filed by HOOK)
6 relationshipsCompanies named in HOOK's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | acquirer | Acquired assets related to HB-400 and HB-500 programs from HOOKIPA Pharma Inc. and Hookipa Biotech GmbH. | 2025-05-22 | View |
| Gilead Sciences, Inc. | GILD | investor | Purchased $21.25 million of common stock and committed to purchase an additional $30.0 million under an amended stock pu | 2023-12-21 | View |
| F. Hoffmann-La Roche Ltd | — | partner | Entered into a Research Collaboration and License Agreement for HB-700 and UCA cancer programs | 2022-10-20 | View |
| Hoffmann-La Roche Inc | — | partner | Entered into a Research Collaboration and License Agreement for HB-700 and UCA cancer programs | 2022-10-20 | View |
| Gilead Sciences, Inc. | GILD | partner | Partner in Amended and Restated Research Collaboration and License Agreement | 2022-03-01 | View |
| Gilead Sciences, Inc. | GILD | partner | Partnered with Hookipa Pharma Inc. for a research collaboration and license agreement regarding HIV and HBV programs, in | 2022-02-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2025-07-29 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-18 | Notice of Delisting or Transfer; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-22 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Departure/El | Agreement | View |
| 2025-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-01-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-02 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-20 | Other Events | View | |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-30 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-26 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-07-10 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2024-06-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-05-23 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-05-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-04-25 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-03-22 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-01-31 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR